As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Longwood Healthcare Leaders Spring Meeting centered on MIT’s Koch Institute via web-conference with leading bio-pharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp. Longwood Healthcare Leaders Meetings drive transparency and collaboration in order to accelerate the translation of discoveries into medicines to help patients. Meetings are invitation-only.
Dr. Chun-Lin Chen, founder & CEO of Medicilon, will participate in the panel discussion titled "Expediting Research for Treatment and Cures" on May 4 at 9:50 am ET. The other invited participants are Raj Devraj (CEO, Rectify Pharmaceuticals), Bill Hinshaw (CEO, Axcella Therapeutics), Peter Lebowitz (Global Oncology Therapeutic Area Head, Janssen), and Reenie McCarthy (CEO, Stealth BioTherapeutics). The panel discussion is moderated by Chen Schor (CEO, Adicet Bio).
Dr. Chun-Lin Chen and our US Business Development team will be joining the Garden Party on MAY 5 at 5:00-7:00 pm ET. We are looking forward to meeting you in this party to discuss how our services and capabilities would support your research needs and expedite your drug discovery and development programs. Wish you a safe trip!
Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world.
Based on key links of drug R&D, we focus on the demand for innovation and the development of the global pharmaceutical industry. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.
18+
More than 18 years of experience in new drug R&D
221
Projects successfully approved with NMPA, FDA, EMA, and TGA
1460+
Active clients worldwide
2440+
Newdrug discovery scientists and service personnel
74000+
Square meters of Laboratory floor space